Case Report

A Chinese Child Presented with Early T Cell Precursor Lymphoblastic Lymphoma

Xiangyang Pu,1,2 Shengyong Deng,1,2 Nange Yin,1,3 Lin Song,3,4,5 Xiangling He,6 and Jianwen Xiao1,7,8

1Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China
2Department of Pediatric Respiratory Medicine, Qianjiang Central Hospital of Chongqing, Chongqing, China
3Department of Pharmacy, Children Hospital of Chongqing Medical University, Chongqing, China
4National Clinical Research Center for Child Health and Disorders, Chongqing, China
5China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing 400014, China
6Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, China
7Chongqing Key Laboratory of Pediatrics, Chongqing, China
8Department of Hematology, Children Hospital of Chongqing Medical University, Chongqing, China

Correspondence should be addressed to Jianwen Xiao; tomahawk6502@sohu.com

Received 20 May 2021; Revised 27 July 2021; Accepted 9 August 2021; Published 28 September 2021

Academic Editor: Saveria Capria

Copyright © 2021 Xiangyang Pu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

T cell lymphoblastic lymphoma (T-LBL) and T cell acute lymphoblastic leukemia (T-ALL) are both hematological tumors that originate from an immature T cell lineage. T-ALL is regarded as the leukemic phase of T-LBL, and a lymphoblast count in bone marrow (BM) < 25% is defined as the cutoff value between T-LBL and T-ALL [1, 2]. The prognosis of T-LBL/ALL remains historically poor. ALL-based chemotherapy and allogenic hematopoietic stem cell transplantation (allo-HSCT) demonstrated effective results, and event-free survival (EFS) in children and adolescents exceeds 80–90% in developed countries [2, 3]. However, the survival of relapsed and/or refractory cases remains poor [2–4]. The early T cell precursors ALL/LBL (ETP-LBL/ALL) are derived from thymic cells at the ETP differentiation stage and are recognized as a high-risk subgroup of T-ALL/LBL [5]. ETP-LBL/ALL occurs in 10–12% or 20–25% of pediatric or adult T-LBL/ALL populations [5–7]. Most of these cases present with ALL at the disease onset, but the ETP-LBL phase is uncommon. Here, we report a patient who presented with ETP-LBL at the disease onset. In this case, ALL developed even despite receiving chemotherapy, but the patient achieved a complete remission with intensive chemotherapy.

1. Introduction

T cell lymphoblastic lymphoma (T-LBL) and T cell acute lymphoblastic leukemia (T-ALL) are both hematological tumors that originate from an immature T cell lineage. T-ALL is regarded as the leukemic phase of T-LBL, and a lymphoblast count in bone marrow (BM) < 25% is defined as the cutoff value between T-LBL and T-ALL [1, 2]. The prognosis of T-LBL/ALL remains historically poor. ALL-based chemotherapy and allogenic hematopoietic stem cell transplantation (allo-HSCT) demonstrated effective results, and event-free survival (EFS) in children and adolescents exceeds 80–90% in developed countries [2, 3]. However, the survival of relapsed and/or refractory cases remains poor [2–4]. The early T cell precursors ALL/LBL (ETP-LBL/ALL) are derived from thymic cells at the ETP differentiation stage and are recognized as a high-risk subgroup of T-ALL/LBL [5]. ETP-LBL/ALL occurs in 10–12% or 20–25% of pediatric or adult T-LBL/ALL populations [5–7]. Most of these cases present with ALL, and the LBL phase is uncommon [6–8]. Here, we report a patient who presented with ETP-LBL at the disease onset. ALL developed even though he subsequently received chemotherapy, and he achieved a complete remission (CR) with intensive chemotherapy.

2. Case Presentation

A 16-year-3-month-old boy was admitted with an irritating dry cough and cervical lymphadenopathy on 28 January 2020. During the physical examination, bilateral cervical
lymph node masses were palpable, and signs of pleural effusion were also noted. Laboratory tests showed normal complete blood cell counts (white blood cells 6.22 × 10^9/L, platelets 295 × 10^9/L, and hemoglobin 161 g/L) and normal lactate dehydrogenase levels (233 U/L). A computed tomography (CT) scan revealed pericardial and right pleural effusion and lymphadenopathy at the cervical area bilaterally and within the mediastinum (Figure 1(a)). A core needle biopsy and subsequent immunohistochemical (IHC) staining of the mediastinum mass was performed for CD3+, CD20−, PAX5−, CD7+, CD34−, Ki-67+ (90%), MPO−, and CD99+ (Figure 2). A sample of the pleural effusion was analyzed which showed that the nucleated cell counts were 31 × 10^9/L, the lymphoblasts were 92%, and there were 55.4% T cell lymphoblasts as detected by flow cytometry (FCM). Positive results for CD7, CD13, and cCD3 and negative results for CD1a, CD4, CD8, CD19, CD20, CD22, CD34, and MPO were confirmed (Figure 3). A diagnosis of ETP-ALL/LBL was considered, and additional IHC samples of the mediastinum mass sample were stained via IHC and were tested. The results showed CD45pro−, CD5−, and CD79a were weak+, CD21 was positive, MUM-1 was negative, CD10 was positive, CK was negative, BCL6 was negative, c-MYC was (40%+), CyclinD1 was negative, ALK was negative, CD30 was negative, and P53 was negative (Figure 2).

A chromosome karyotype of the pleural effusion sample was obtained using the International System of Human Cytogenetic Nomenclature 2009 (ISCN-2009) [2]; 43−50, X, Y, add(7)(p13), 9;((9)(q10), 14, 16, +22, del(22)(q13), inc [CP8] (Figure 3). BM samples were acquired at the bilateral posterior superior iliac area, and blast cells were not detected by a BM smear, biopsy, or via FCM.

Samples were taken from the mediastinum mass, and whole exome sequencing (WES) and RNA sequencing (RNAseq) were performed. FBXW7 and GATA3 somatic mutations were detectable by WES (Table 1); transcripts of FBXW7, GATA3, JAK1, and NCOR1 were confirmed by RNAseq (Table 2).

A diagnosis of ETP-LBL was given based on previous literature reports [5–8], and the patient was classified as stage III by the revised International Pediatric Non-Hodgkin’s Lymphoma Staging System [9]. He was treated with a modified BFM-LBL-95 protocol and was placed in an intermediate-risk (IR) group at the initial diagnosis [10]; the detail of the disease evaluation, risk group classification, treatment courses, dosages, and intrathecal injections had been listed at Supplementary Tables S1–S5, respectively; his treatment response was evaluated by BM, CT, or positron emission tomography/computed tomography (PET/CT) imaging at different time points (TP) as the protocol required. On day 15 and day 33 (TP1 or TP2) during the course of the induction of remission I, the BM smear showed 29.5% and 80% blast cells, FCM had 29% and 55.4% ETP lymphoblasts (Figures 4(a) and 4(b)), and a chest CT scan revealed an unchanged mediastinum mass (Figure 1(b)).

He was considered to have progressive disease (PD) and refractory disease at TP2 [5, 6], and two standard courses A of the HyperCVAD protocol [11] were administered. After the 1st course, lymphoblasts were no longer detected in the BM during the evaluation of the BM smear (Figure 4(c)); the CT scan showed a partial remission (PR) [5, 6], which was subsequently monitored by CT scans (Figure 1(c)). He achieved CR after the 2nd course A, which was monitored by using BM smears (Figure 4(d)) and PET-CT scans (Figure 1(d)). The minimal residual disease (MRD) level was also detected by FCM [12], and a negative result was obtained (<10−4). Allo-HSCT was declined by the family, and he was treated with the CCLG-ALL-2008 protocol for the high-risk (HR) group [12]. Up until June 2021, he was alive without any evidence of a relapse.

3. Discussion

ETP-ALL/LBL is a recently described subgroup of T-ALL/LBL according to the World Health Organization criteria from 2016 (WHO 2016) [4]; usually, these cases are aggressive and present with ETP-ALL, whereas pediatric ETP-LBL is uncommon (20–30% in adult T-ALL/LBL, pediatric data are absent). In the presented case, we reported a child who suffered from ETP-LBL without BM infiltration at the onset.

ETP-ALL/LBL patients are distinguished from non-ETPs by FCM and genomic signatures. ETP-ALL/LBL is immunophenotypically defined by weak or absent expression of T cell markers (CD1a, CD5, and CD8) and positive expression of at least one hematopoietic stem cell (HSC) and/or myeloid markers (CD13, CD33, CD34, CD117, and HLA-DR). The diagnosis of T-LBL was based on the pathological results and IHC staining, but not all the T cell, HSC, and myeloid markers were evaluated. Fortunately, the patient was diagnosed with ETP-ALL/LBL by FCM detected in a pleural effusion sample. FCM is an important technique to subclassify T-ALL/LBL, and all these T-ALL/LBL samples should be evaluated if possible.

Genomic signatures of ETP-ALL/LBL patients also exhibit unique genotypes compared with those of non-ETPs patients [7, 8]. Recurrent mutations were not only identified in the genes involved in T-lymphoid development or oncogenesis because myeloid markers were also detectable. Activating mutations encoding cytokine receptors and mediating the RAS signal transduction system (NRAS, KRAS, FLT3, and JAK1), inactivating mutations encoding transcription factors (GATA3, ETV6, and RUNX1) and histone repair (EZH2 and EP300) during hematopoietic stem cell development are common in ETP-ALL/LBL patients [5, 6, 13]. WES and RNAseq of LN samples have been evaluated, common gene mutations and transcripts (FBXW7, NOTCH1, and JAK1) in T-ALL/LBL have been identified, and unique genomic signatures of ETP-ALL/LBL have also been identified. This suggests that gene analysis can assist in the diagnosis of ETPs without using FCM detection.
The best treatment and the prognosis for ETPs patients is unclear. Treatment responses and outcomes for ETP-ALL/LBL patients treated with chemotherapy were poorer than those for non-ETP-ALL/LBL adult patients, and it was reported that these cases benefit from allo-HSCT [4–6]. Although early reports of pediatric ETP-ALL showed a poor prognosis, recent clinical trials of COGALL0434 and UKALL2003 showed that the prognosis of ETP-ALL was similar to that of other T-ALLs [14, 15]. However, ETP-LBL was uncommon, but the treatment experience was limited. The patient in this case report was treated with a modified BFM-LBL-95 protocol, the ALL-based classic protocol for T-LBL patients, but he was considered to have refractory disease and infiltration into the BM. It was reported that adults benefited from the hyperCVAD protocol [5, 6], and in our patient, two courses A were administered, but course B was omitted due to financial constraints. The patient obtained CR, and chemotherapy was continued.

In conclusion, we reported a case of ETP-LBL that took an aggressive clinical course. Our case revealed that clinicians should pay attention to the possibility of ETP-LBL in common T-LBL cases, and FCM and genomic signatures are important to distinguish ETP-LBL. Further studies are needed to research the most effective treatment for ETP-ALL/LBL patients.
Table 1: Results of whole exome sequencing.

| Genes     | Chromosome coordinate | Mutation site          | Mutation frequency (%) |
|-----------|-----------------------|------------------------|------------------------|
| FBXW7     | chr4: 153247366       | c.1436G > A (p.Arg479Gln) | 38.3                   |
| GATA3     | chr10: 8106004        | c.827G > A (p.Arg276Gln) | 38.8                   |
| GATA3     | chr10: 8105986        | c.811_812dup (p.(Q_hr272ArgfsTer24) | 26.7                   |

Table 2: Results of RNA sequencing.

| Gene mutations | Mutation type     | Mutation frequency (%) |
|----------------|-------------------|------------------------|
| FBXW7 R479Q    | Missense mutation | 51.9                   |
| GATA3 R276Q    | Missense mutation | 68.8                   |
| GATA3 T270fs   | Frameshift mutation | 24.4                   |
| JAK1 L783F     | Missense mutation | 58.5                   |
| NCOI1 Y1435*   | Truncating mutation | 34.6                   |
| NOTCH1 V1721E  | Missense mutation | 34.1                   |
Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

JX, XP, and SD prepared the original draft. LS and JX helped with the design of the project. JX treated the patient and supervised the manuscript. All authors reviewed the final version.

Acknowledgments

The authors thank the patient and his family who participated in this study. This research was supported by the National Natural Science Foundation of China (Project no. 81900162) and the Chongqing Science and Technology Commission of PR China (Project no. cstc2018jysy-jsyjX0015).

Supplementary Materials

Table S1: disease evaluation. Table S2: risk group. Table S3: schedule of the protocol. Table S4: modified NHL-LBL-95 protocol. Table S5: schedule of intrathecal injections. (Supplementary Materials)

References

[1] B. Burkhardt and M. L. Hermiston, “Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities,” British Journal of Haematology, vol. 185, no. 6, pp. 1158–1170, 2019.

[2] B. Burkhardt, S. Mueller, T. Khanam, and S. L. Perkins, “Current status and future directions of t-lymphoblastic lymphoma in children and adolescents,” British Journal of Haematology, vol. 173, no. 4, pp. 545–559, 2016.

[3] M. J. You, L. J. Medeiros, and E. D. Hsi, “T-lymphoblastic leukemia/lymphoma,” American Journal of Clinical Pathology, vol. 144, no. 3, pp. 411–422, 2015.

[4] W. Guan, Y. Jing, L. Dou, M. Wang, Y. Xiao, and L. Yu, “Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia,” Leukemia and Lymphoma, vol. 61, no. 4, pp. 855–861, 2020.

[5] N. Jain, A. V. Lamb, S. O’Brien et al., “Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype,” Blood, vol. 127, no. 15, pp. 1863–1869, 2016.

[6] J. Bond, C. Graux, L. Lhermitte et al., “Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study,” Journal of Clinical Oncology, vol. 35, no. 23, pp. 2683–2691, 2017.

[7] M. Ma, X. Wang, J. Tang et al., “Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia,” Frontiers of Medicine, vol. 6, no. 4, pp. 416–420, 2012.

[8] Y. Jiang, A. Maiti, and Z. Kanaan, “A young man with a mass: non-early precursor t-cell lymphoblastic lymphoma,” The American Journal of Medicine, vol. 132, no. 1, pp. 58–60, 2019.

[9] A. Rosolen, S. L. Perkins, C. R. Pinkerton et al., “Revised international pediatric non-hodgkin lymphoma staging system,” Journal of Clinical Oncology, vol. 33, no. 18, pp. 2112–2118, 2015.

[10] C. Y. Zheng, J. W. Xiao, J. Yu, and Y. G. Chen, “Prognosis and side effects of T-NHL-2009 protocol on treatment of lymphoblastic lymphoma in Children,” Clinics in Laboratory Medicine, vol. 14, no. 13, pp. 1883–1887, 2017.

[11] C. R. Rausch, E. J. Jabbour, H. M. Kantarjian, and T. M. Kadia, “Optimizing the use of the hyperCVAD regimen: clinical vignettes and practical management,” Cancer, vol. 126, no. 6, pp. 1152–1160, 2020.

[12] L. Cui, Z.-G. Li, Y.-H. Chai et al., “Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: the first nation-wide prospective multicenter study in China,” American Journal of Hematology, vol. 93, no. 7, pp. 913–920, 2018.

[13] O. C. Pugliannini and N. Papadantonakis, “Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts,” Therapeutic Advances in Hematology, vol. 11, Article ID 2040620720929475, 2020.

[14] S. S. Winter, K. P. Dunsmore, M. Devidas et al., “Improved survival for children and young adults with t-lineage acute
lymphoblastic leukemia: results from the children’s oncology group AALL0434 methotrexate randomization,” *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, vol. 36, no. 29, pp. 2926–2934, 2018.

[15] K. Patrick, R. Wade, N. Goulden et al., “Outcome for children and young people with early t-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, ukall 2003,” *British Journal of Haematology*, vol. 166, pp. 421–4, 2014.